Quantum Biopharma (NASDAQ:QNTM - Get Free Report) was upgraded by investment analysts at Singular Research to a "moderate buy" rating in a research note issued on Wednesday,Zacks.com reports.
Separately, Wall Street Zen upgraded shares of Quantum Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, June 7th.
View Our Latest Stock Report on QNTM
Quantum Biopharma Stock Up 17.9%
Shares of NASDAQ QNTM traded up $4.12 during trading on Wednesday, reaching $27.13. The company had a trading volume of 620,606 shares, compared to its average volume of 945,845. Quantum Biopharma has a 12-month low of $2.70 and a 12-month high of $38.25. The business's 50-day moving average is $12.54 and its 200 day moving average is $7.97. The stock has a market cap of $78.95 million, a PE ratio of -1.70 and a beta of 0.54.
Quantum Biopharma (NASDAQ:QNTM - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($0.37) by ($1.04). The company had revenue of $2.09 million for the quarter, compared to the consensus estimate of $2.09 million. On average, analysts anticipate that Quantum Biopharma will post -3.27 earnings per share for the current year.
Institutional Investors Weigh In On Quantum Biopharma
An institutional investor recently raised its position in Quantum Biopharma stock. AdvisorShares Investments LLC grew its stake in shares of Quantum Biopharma Ltd. (NASDAQ:QNTM - Free Report) by 163.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 69,078 shares of the company's stock after acquiring an additional 42,845 shares during the quarter. AdvisorShares Investments LLC owned about 3.60% of Quantum Biopharma worth $254,000 as of its most recent SEC filing. Institutional investors and hedge funds own 1.24% of the company's stock.
About Quantum Biopharma
(
Get Free Report)
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.
See Also
Before you consider Quantum Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quantum Biopharma wasn't on the list.
While Quantum Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
